CA2252896C - Inactivation resistant factor viii - Google Patents

Inactivation resistant factor viii Download PDF

Info

Publication number
CA2252896C
CA2252896C CA002252896A CA2252896A CA2252896C CA 2252896 C CA2252896 C CA 2252896C CA 002252896 A CA002252896 A CA 002252896A CA 2252896 A CA2252896 A CA 2252896A CA 2252896 C CA2252896 C CA 2252896C
Authority
CA
Canada
Prior art keywords
fviii
protein
nucleic acid
apc
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002252896A
Other languages
English (en)
French (fr)
Other versions
CA2252896A1 (en
Inventor
Randal J. Kaufman
Steven W. Pipe
Kagehiro Amano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA2252896A1 publication Critical patent/CA2252896A1/en
Application granted granted Critical
Publication of CA2252896C publication Critical patent/CA2252896C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002252896A 1996-04-24 1997-04-24 Inactivation resistant factor viii Expired - Fee Related CA2252896C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US1778596P 1996-05-15 1996-05-15
US60/016,117 1996-05-15
US60/017,785 1996-05-15
PCT/US1997/006563 WO1997040145A1 (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Publications (2)

Publication Number Publication Date
CA2252896A1 CA2252896A1 (en) 1997-10-30
CA2252896C true CA2252896C (en) 2009-03-10

Family

ID=26688196

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002252896A Expired - Fee Related CA2252896C (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Country Status (10)

Country Link
US (2) US6838437B2 (enExample)
EP (3) EP1754718B1 (enExample)
JP (2) JP3987114B2 (enExample)
AT (2) ATE319817T1 (enExample)
AU (1) AU3202797A (enExample)
CA (1) CA2252896C (enExample)
DE (2) DE69740154D1 (enExample)
DK (1) DK1754718T3 (enExample)
PT (1) PT1754718E (enExample)
WO (1) WO1997040145A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713303B2 (en) * 1995-06-12 1999-11-25 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
ATE319817T1 (de) 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
WO1999041385A1 (en) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
JP2005518181A (ja) * 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
WO2006067230A1 (en) * 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
AU2006233638A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2008005847A2 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
MX351220B (es) * 2010-11-05 2017-10-05 Baxalta GmbH Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
US9511123B2 (en) 2011-10-18 2016-12-06 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
EP2768522B1 (en) 2011-10-18 2016-07-27 CSL Behring GmbH Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
US20150337028A1 (en) * 2012-09-12 2015-11-26 Centre For Bioseparation Technology-Vit Double Mutant Coagulation Factor VIII and Methods Thereof
MX2015006738A (es) 2012-11-29 2015-08-05 Bayer Healthcare Llc Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos.
RU2015125349A (ru) * 2012-11-29 2017-01-10 Байер Хелскеа Ллк МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС)
US9914764B2 (en) 2013-03-15 2018-03-13 Bayer Healthcare, Llc Variant factor VIII polypeptides and methods of their production and use
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
ES2844232T3 (es) 2014-07-02 2021-07-21 CSL Behring Lengnau AG Factor de Von Willebrand modificado
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2978134A1 (en) * 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Compounds for improving the half-life of von willebrand factor
SG10201910900WA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
MX2017014503A (es) 2015-05-22 2018-08-01 CSL Behring Lengnau AG Polipeptidos de factor de von willebrand truncado para tratar hemofilia.
WO2017087391A1 (en) 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
KR20190073576A (ko) 2016-11-11 2019-06-26 체에스엘 베링 렝나우 아게 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CN120865384A (zh) * 2018-10-23 2025-10-31 费城儿童医院 用于调节因子viii功能的组合物和方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN114828870A (zh) * 2019-12-06 2022-07-29 费城儿童医院 用于调节因子viii功能的组合物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
FI922204A0 (fi) 1989-11-17 1992-05-14 Novo Nordisk As Proteinkomplex med faktor viii:c- aktivitet och framstaellning av desamma.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
ATE319817T1 (de) * 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii

Also Published As

Publication number Publication date
WO1997040145A1 (en) 1997-10-30
JP3987114B2 (ja) 2007-10-03
EP1754718A2 (en) 2007-02-21
US6838437B2 (en) 2005-01-04
EP1754718A3 (en) 2007-05-16
CA2252896A1 (en) 1997-10-30
PT1754718E (pt) 2011-07-13
DE69735421D1 (de) 2006-05-04
DE69735421T2 (de) 2006-10-19
US20060014683A1 (en) 2006-01-19
JP4250661B2 (ja) 2009-04-08
EP2202242A1 (en) 2010-06-30
AU3202797A (en) 1997-11-12
DE69740154D1 (de) 2011-05-05
EP0910628B1 (en) 2006-03-08
ATE319817T1 (de) 2006-03-15
ATE502958T1 (de) 2011-04-15
JP2007228973A (ja) 2007-09-13
JP2000511407A (ja) 2000-09-05
DK1754718T3 (da) 2011-07-18
EP1754718B1 (en) 2011-03-23
US7459534B2 (en) 2008-12-02
EP0910628A4 (en) 2001-05-02
US20020132306A1 (en) 2002-09-19
EP0910628A1 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
CA2252896C (en) Inactivation resistant factor viii
WO1997040145A9 (en) Inactivation resistant factor viii
US20120190623A1 (en) Inactivation Resistant Factor VIII
US20040092442A1 (en) Inactivation resistant factor VIII
AU717686B2 (en) Modified factor VIII
AU2007269233B2 (en) Method of producing Factor VIII proteins by recombinant methods
AU693837B2 (en) Hybrid human/animal factor VIII
US6770744B2 (en) Modified factor VIII
AU747644B2 (en) Modified factor VIII
US20030068785A1 (en) Modified factor VIII
AU5023700A (en) Modified factor viii
US20140357565A1 (en) Method of producing factor viii proteins by recombinant methods
JP2005511038A (ja) 第ｖｉｉｉ因子ｃ２ドメインのバリアント
Donath et al. Characterization of des-(741–1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa
US20030148953A1 (en) Inactivation resistant factor VIII
US20090203077A1 (en) Method of producing factor viii proteins by recombinant methods
ES2363873T3 (es) Factor viii resistente a la inactivación.
HK1178545A (en) Method of producing factor viii proteins by recombinant methods

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160425